Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ATOD2
MCID: DRM054
MIFTS: 51

Dermatitis, Atopic, 2 (ATOD2)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dermatitis, Atopic, 2

About this section

MalaCards integrated aliases for Dermatitis, Atopic, 2:

Name: Dermatitis, Atopic, 2 57 71
Atopic Dermatitis 2 11 28 5 14
Atod2 57 11 73
Dermatitis, Atopic, Susceptibility to, 2 57 12
Dermatitis, Atopic, 2, Susceptibility to 28 5
Dermatitis, Atopic, Type 2 38
Dermatitis, Atopic 2 57
Dermatitis Atopic 2 73
Dermatitis, Atopic 71
Atopic Eczema 73

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Immune diseases Skin diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:0110098
OMIM® 57 605803
OMIM Phenotypic Series 57 PS603165
MeSH 43 D003876
MedGen 40 C1853965
UMLS 71 C0011615 C1853965
Sources

Summaries for Dermatitis, Atopic, 2

About this section

UniProtKB/Swiss-Prot: 73 Atopic dermatitis is a complex, inflammatory disease with multiple alleles at several loci thought to be involved in the pathogenesis. It commonly begins in infancy or early childhood and is characterized by a chronic relapsing form of skin inflammation, a disturbance of epidermal barrier function that culminates in dry skin, and IgE- mediated sensitization to food and environmental allergens. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee.

MalaCards based summary: Dermatitis, Atopic, 2, also known as atopic dermatitis 2, is related to ichthyosis vulgaris and ichthyosis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis, Atopic, 2 is FLG (Filaggrin), and among its related pathways/superpathways are Sphingolipid metabolism and S-1P Stimulated Signaling. The drugs Zinc cation and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and pituitary.

Disease Ontology: 11 An atopic dermatitis conferred by variation in the FLG gene on chromosome 1q21.

More information from OMIM: 605803 PS603165
Sources

Related Diseases for Dermatitis, Atopic, 2

About this section

Diseases in the Dermatitis, Atopic family:

Dermatitis, Atopic, 2 Dermatitis, Atopic, 3
Dermatitis, Atopic, 4 Dermatitis, Atopic, 5
Dermatitis, Atopic, 6 Dermatitis, Atopic, 7
Dermatitis, Atopic, 8 Dermatitis, Atopic, 9

Diseases related to Dermatitis, Atopic, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 ichthyosis vulgaris 30.5 FLG-AS1 FLG
2 ichthyosis 30.1 FLG-AS1 FLG ELOVL1
3 immunodeficiency 85 and autoimmunity 11.3
4 skin disease 10.9
5 rhinitis 10.8
6 chronic rhinitis 10.8
7 food allergy 10.8
8 ehlers-danlos syndrome, arthrochalasia type, 1 10.7
9 asthma 10.7
10 allergic asthma 10.7
11 allergic disease 10.6
12 urticaria 10.6
13 exanthem 10.5
14 contact dermatitis 10.5
15 attention deficit-hyperactivity disorder 10.4
16 allergic contact dermatitis 10.4
17 milk allergy 10.4
18 respiratory allergy 10.4
19 viral infectious disease 10.4
20 asthma-related traits 4 10.3
21 respiratory failure 10.3
22 neurodermatitis 10.3
23 conjunctivitis 10.3
24 type 1 diabetes mellitus 10.3
25 proteasome-associated autoinflammatory syndrome 1 10.3
26 herpes simplex 10.3
27 oculodentodigital dysplasia 10.3
28 acne 10.3
29 eczema herpeticum 10.3
30 hypereosinophilic syndrome 10.3
31 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
32 ceroid lipofuscinosis, neuronal, 5 10.2
33 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 10.2
34 anxiety 10.2
35 tatton-brown-rahman syndrome 10.2
36 rickets 10.2
37 egg allergy 10.2
38 nutritional deficiency disease 10.2
39 seborrheic dermatitis 10.2
40 alopecia 10.2
41 children's interstitial lung disease 10.2
42 cone-rod dystrophy 2 10.1
43 major depressive disorder 10.1
44 angina pectoris 10.1
45 endocarditis 10.1
46 common cold 10.1
47 toxic shock syndrome 10.1
48 dermatographia 10.1
49 measles 10.1
50 chickenpox 10.1

Graphical network of the top 20 diseases related to Dermatitis, Atopic, 2:



Diseases related to Dermatitis, Atopic, 2
Sources

Symptoms & Phenotypes for Dermatitis, Atopic, 2

About this section

Clinical features from OMIM®:

605803 (Updated 08-Dec-2022)

UMLS symptoms related to Dermatitis, Atopic, 2:


pruritus; exanthema
Sources

Drugs & Therapeutics for Dermatitis, Atopic, 2

About this section

Drugs for Dermatitis, Atopic, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 286)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
2
Coal tar Approved Phase 4 8007-45-2
3
Zinc oxide Approved Phase 4 1314-13-2
4
Desonide Approved, Investigational Phase 4 638-94-8 5311066
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Montelukast Approved Phase 4 158966-92-8 5281040
8
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
9
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
12
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8 4474933
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
14
Levocetirizine Approved Phase 4 130018-77-8 1549000
15
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
16
Petrolatum Approved, Investigational Phase 4 8009-03-8
17
Desoximetasone Approved Phase 4 382-67-2 5311067
18
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
19
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
22
Promethazine Approved, Investigational Phase 4 60-87-7 4927
23
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
24
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
25
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
26
Upadacitinib Approved, Investigational Phase 4 1310726-60-3 76829165 58557659
27
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
28
Dicloxacillin Approved, Investigational, Vet_approved Phase 4 3116-76-5 18381
29
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
30
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
31
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6509979
32
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
33
Lactitol Approved, Investigational Phase 4 585-86-4 157355
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
35
Capric acid Experimental Phase 4 59906-14-8, 334-48-5 2969
36
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
37
Cortisone Experimental Phase 4 53-06-5 222786
38
Clobetasone butyrate Phase 4 2792
39 Calcium, Dietary Phase 4
40 Keratolytic Agents Phase 4
41 Eusol Phase 4
42
Sodium Hypochlorite Phase 4
43 Bronchodilator Agents Phase 4
44 Anti-Allergic Agents Phase 4
45 Xhance Phase 4
46 Epinephryl borate Phase 4
47 Acidophilus Phase 4
48 Histamine H1 Antagonists, Non-Sedating Phase 4
49 Leukotriene Antagonists Phase 4
50 Neuroprotective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 986)
# Name Status NCT ID Phase Drugs
1 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
2 A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study Unknown status NCT03257215 Phase 4 Stoss vitamin D;Daily vitamin D;Stoss placebo;Daily placebo
3 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
4 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
5 Effects of Interleukin (IL)-4/IL-13 Blockade on the Structure and Function of Cutaneous Sensory Nerves: An Open-label, Single-arm Longitudinal Study With Dupilumab Unknown status NCT04520308 Phase 4 Dupilumab Only Product
6 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
7 Comparative, Multicentre, Randomized, Double-blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With So-called 'Red Face' Lesions of the Head and Neck. Completed NCT00690105 Phase 4 tacrolimus 0.1%;fluticasone 0.005 %
8 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
9 A Randomized, Double-Blind, Intra-Individual, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Different Application Rates of Topically Applied Crisaborole Ointment 2% in Adult Subjects With Mild to Moderate Atopic Dermatitis Completed NCT03868098 Phase 4 Crisaborole 2%;Placebo ointment
10 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4 Investigational OTC Cream;0.05% Desonide Cream
11 Clinical Evaluation of the Effect of Moisturising Cream on Skin Moisture in Atopic Dermatitis Completed NCT00846235 Phase 4
12 Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis. Completed NCT00689832 Phase 4 Tacrolimus 0.03%;Fluticasone 0.005%
13 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
14 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
15 Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis Completed NCT02680301 Phase 4 0.1% triamcinolone CREAM;0.1% triamcinolone OINTMENT
16 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
17 Montelukast as Adjunct Treatment in Children With Atopic Dermatitis Completed NCT02534467 Phase 4 Montelukast
18 Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan Cream Completed NCT00185510 Phase 4 Methylprednisolone Aceponate (Advantan, BAY86-4862);Placebo
19 A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis Completed NCT04823130 Phase 4 Dupilumab SAR231893
20 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
21 Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
22 The Efficacy and Safety of Tacrolimus Ointment in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT01782729 Phase 4 Tacrolimus
23 The Efficacy and Safety of Tacrolimus Ointment in Adult Patients With Moderate to Severe Atopic Dermatitis Completed NCT01828879 Phase 4 Tacrolimus
24 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
25 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
26 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
27 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
28 Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study Completed NCT02589392 Phase 4
29 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
30 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
31 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
32 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
33 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
34 Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
35 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
36 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
37 The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Completed NCT04114097 Phase 4 Betnovate, betamethasone dipropionate ointment 0.1% and placebo;Protopic, tacrolimus ointment 0.1%
38 A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS Completed NCT03356977 Phase 4 Crisaborole ointment 2%
39 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
40 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
41 A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis Completed NCT01915914 Phase 4 Fluticasone propionate
42 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
43 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
44 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
45 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
46 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
47 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
48 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
49 Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion Completed NCT00925730 Phase 4 Pimecrolimus
50 Effect of Sublingual Immunotherapy With Mite Extract in Patients With Atopic Dermatits: Placebo-controlled Double-blind Randomized Study Completed NCT03388866 Phase 4 Mite extract sublingual immunotherapy (SLIT)

Search NIH Clinical Center for Dermatitis, Atopic, 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
Doxepin
Doxepin Hydrochloride
fluocinolone
Fluocinolone Acetonide
methdilazine
Methdilazine hydrochloride
Pimecrolimus
Tacrolimus
Trimeprazine
trimeprazine tartrate
Triprolidine
Triprolidine Hydrochloride
Zinc Oxide
Sources

Genetic Tests for Dermatitis, Atopic, 2

About this section

Genetic tests related to Dermatitis, Atopic, 2:

# Genetic test Affiliating Genes
1 Atopic Dermatitis 2 28 FLG
2 Dermatitis, Atopic, 2, Susceptibility to 28
Sources

Anatomical Context for Dermatitis, Atopic, 2

About this section

Organs/tissues related to Dermatitis, Atopic, 2:

MalaCards : Skin, T Cells, Pituitary, Heart, Bone, Breast, B Cells
Sources

Publications for Dermatitis, Atopic, 2

About this section

Articles related to Dermatitis, Atopic, 2:

(show top 50) (show all 2938)
# Title Authors PMID Year
1
Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. 57 5
17291859 2007
2
Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. 57 5
17030239 2006
3
Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. 57 5
16815158 2006
4
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. 57 5
16550169 2006
5
Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. 57 5
16444271 2006
6
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. 62 5
17417636 2007
7
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21. 62 57
16912508 2006
8
From atopic dermatitis to asthma: the atopic march. 5
20674819 2010
9
Analysis of four prevalent filaggrin mutations (R501X, 2282del4, R2447X and S3247X) in Austrian and German patients with atopic dermatitis. 5
19874431 2010
10
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. 57
11279517 2001
11
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. 62
36387062 2023
12
Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study. 62
35842231 2022
13
Group Recommends Clinical Instruments to Measure Atopic Eczema Burden. 62
36472604 2022
14
Prenatal diet, plasma micronutrients/metabolome and inflammatory status influence the development of atopic eczema in early childhood. 62
36321872 2022
15
Evaluation of a Comprehensive Web-Based Educational Program for Nursing Staff on Atopic Eczema and Its Management. 62
36255402 2022
16
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial. 62
35763390 2022
17
Preventing atopic eczema: vitamin D supplementation another piece of the puzzle? 62
35986638 2022
18
Guidelines for the Management of Atopic Dermatitis in Children: A Systematic Review. 62
36323240 2022
19
European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. 62
36056736 2022
20
Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention of Atopic Dermatitis in Infants: A Systematic Review and Meta-Analysis of Randomized Trials. 62
36161401 2022
21
Severe atopic eczema treated by dupilumab in a child with keratitis-ichthyosis-deafness syndrome. 62
36066012 2022
22
Eczema-related Web Search Data in Sweden: Investigating Search Patterns and the Influence of Weather. 62
36065747 2022
23
Neonatal Bacillus Calmette-Guérin Vaccination to Prevent Early-Life Eczema: A Systematic Review and Meta-analysis. 62
36125788 2022
24
Continuous Rather Than Solely Early Farm Exposure Protects From Hay Fever Development. 62
36356926 2022
25
Have the prevalence of eczema symptoms increased in the Mexican pediatric population? Prevalence and associated factors according to Global Asthma Network Phase I. 62
36267354 2022
26
Patch test results to extracts of synthetic garments in textile dye positive patients. 62
35818106 2022
27
Skin Prick Test in Educating Population of Rural Part of Eastern India and Promoting Health in Allergic Rhinitis: An Epidemiological Study. 62
36452796 2022
28
A bite by the emerald snake, Hapsidophrys smaragdinus Schlegel, 1837 (Colubridae, Colubrinae) causing atopic eczema with comments on the formal documentation of non-front-fanged snakebites. 62
35940358 2022
29
Line-field confocal optical coherence tomography of psoriasis, eczema and lichen planus: a case series with histopathological correlation. 62
35666617 2022
30
A small proline-rich protein (SPRR) gene variant contributes to atopic eczema and eczema-associated asthma susceptibility. 62
36457670 2022
31
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. 62
36223090 2022
32
Efficacy of Acupuncture for Treatment of Atopic Eczema and Chronic Eczema: A Systematic Review and Meta-analysis. 62
36200506 2022
33
Cochrane corner: Phototherapy for atopic eczema. 62
36161367 2022
34
European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. 62
35980214 2022
35
Prenatal and child vitamin D levels and allergy and asthma in childhood. 62
36057646 2022
36
Is Patch Test Necessary in Children to Solve the Clinical Conundrum of Foot Eczema. 62
34999604 2022
37
A Case of Ichthyosis Vulgaris and the Use of 70% Glycolic Acid Chemical Peels for Management. 62
36159354 2022
38
Facial atopic dermatitis may be exacerbate by masks: Insights from a multicenter, teledermatology, prospective study during COVID-19 pandemic. 62
36177781 2022
39
Taiwan guidelines for the diagnosis and management of pediatric atopic dermatitis: Consensus statement of the Taiwan Academy of Pediatric Allergy, Asthma and Immunology. 62
35487815 2022
40
Past, Present, and Future Shared Decision-making Behavior Among Patients With Eczema and Caregivers. 62
35793092 2022
41
Unveiling the Ability of Witch Hazel (Hamamelis virginiana L.) Bark Extract to Impair Keratinocyte Inflammatory Cascade Typical of Atopic Eczema. 62
36012541 2022
42
An Overview of the Latest Metabolomics Studies on Atopic Eczema with New Directions for Study. 62
35955924 2022
43
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce. 62
36018221 2022
44
Mixed-methods evaluation of a nurse-led allergy clinic model in primary care: Feasibility trial. 62
36036238 2022
45
Th1 regulatory events by infectious pathogens, herpes zoster and herpes simplex viruses: prospects for therapeutic options for atopic eczema. 62
36090727 2022
46
Genetic Variants in Epidermal Differentiation Complex Genes as Predictive Biomarkers for Atopic Eczema, Allergic Sensitization, and Eczema-Associated Asthma in a 6-Year Follow-Up Case-Control Study in Children. 62
36013110 2022
47
Adult atopic eczema and the risk of dementia: A population-based cohort study. 62
35367295 2022
48
Early life exposures and development of allergic disease in infants with familial risk: Results from ongoing probiotic intervention trials. 62
35989564 2022
49
From the Cochrane Library: Phototherapy for atopic eczema. 62
35276284 2022
50
Home treatment of single cutaneous warts combining face-to-face and teledermatology consultation: A new perspective. 62
35441776 2022
Sources

Variations for Dermatitis, Atopic, 2

About this section

ClinVar genetic disease variations for Dermatitis, Atopic, 2:

5 (show all 16)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLG-AS1, FLG NM_002016.2(FLG):c.487G>T (p.Gly163Ter) SNV Pathogenic
 523875 rs1214424848 GRCh37: 1:152286875-152286875
GRCh38: 1:152314399-152314399
2 FLG NM_002016.2(FLG):c.7837A>T (p.Arg2613Ter) SNV Pathogenic
 546021 rs567795279 GRCh37: 1:152279525-152279525
GRCh38: 1:152307049-152307049
3 FLG NM_002016.2(FLG):c.5170G>T (p.Gly1724Ter) SNV Pathogenic
 522879 rs747301529 GRCh37: 1:152282192-152282192
GRCh38: 1:152309716-152309716
4 FLG NM_002016.2(FLG):c.2476C>T (p.Arg826Ter) SNV Pathogenic
 265156 rs115746363 GRCh37: 1:152284886-152284886
GRCh38: 1:152312410-152312410
5 FLG NM_002016.2(FLG):c.2282_2285del (p.Ser761fs) MICROSAT Pathogenic
Risk Factor
Conflicting Interpretations Of Pathogenicity
 16320 rs558269137 GRCh37: 1:152285077-152285080
GRCh38: 1:152312601-152312604
6 FLG NM_002016.2(FLG):c.7339C>T (p.Arg2447Ter) SNV Pathogenic
Pathogenic
 50932 rs138726443 GRCh37: 1:152280023-152280023
GRCh38: 1:152307547-152307547
7 FLG NM_002016.2(FLG):c.1501C>T (p.Arg501Ter) SNV Pathogenic
Pathogenic
Risk Factor
 16319 rs61816761 GRCh37: 1:152285861-152285861
GRCh38: 1:152313385-152313385
8 FLG NM_002016.2(FLG):c.9901A>T (p.Arg3301Ter) SNV Likely Pathogenic
 1705697 GRCh37: 1:152277461-152277461
GRCh38: 1:152304985-152304985
9 FLG NM_002016.2(FLG):c.7661C>G (p.Ser2554Ter) SNV Risk Factor
 16321 rs121909626 GRCh37: 1:152279701-152279701
GRCh38: 1:152307225-152307225
10 FLG NM_002016.2(FLG):c.6950_6957del (p.Ala2316_Ser2317insTer) DEL Likely Pathogenic
 419605 rs578184315 GRCh37: 1:152280405-152280412
GRCh38: 1:152307929-152307936
11 FLG NM_002016.2(FLG):c.3321del (p.Gly1109fs) DEL Risk Factor
 420115 rs200519781 GRCh37: 1:152284041-152284041
GRCh38: 1:152311565-152311565
12 FLG NM_002016.2(FLG):c.9740C>A (p.Ser3247Ter) SNV Likely Pathogenic
 50930 rs150597413 GRCh37: 1:152277622-152277622
GRCh38: 1:152305146-152305146
13 FLG NM_002016.2(FLG):c.10849C>T (p.Gln3617Ter) SNV Likely Pathogenic
 1033883 rs1651769432 GRCh37: 1:152276513-152276513
GRCh38: 1:152304037-152304037
14 FLG NM_002016.2(FLG):c.7801G>A (p.Asp2601Asn) SNV Uncertain Significance
 445660 rs146849256 GRCh37: 1:152279561-152279561
GRCh38: 1:152307085-152307085
15 FLG NM_002016.1(FLG):c.2379_2394delinsTCCTCAG (p.Leu794_Ser798delinsProGln) INDEL Uncertain Significance
 547860 rs1553213630 GRCh37: 1:152284968-152284983
GRCh38: 1:152312492-152312507
16 FLG-AS1, FLG NM_002016.2(FLG):c.557dup (p.Asn186fs) DUP Not Provided
 419550 rs771721862 GRCh37: 1:152286804-152286805
GRCh38: 1:152314328-152314329
Sources

Expression for Dermatitis, Atopic, 2

About this section
Search GEO for disease gene expression data for Dermatitis, Atopic, 2.
Sources

Pathways for Dermatitis, Atopic, 2

About this section

Pathways related to Dermatitis, Atopic, 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sphingolipid metabolism 66
Show member pathways
 11.41 CERS4 ASAH2 ACER1
2
S-1P Stimulated Signaling 64
11.14 ASAH2 ACER1
3
Sphingolipid pathway 74
Show member pathways
 10.47 CERS4 ASAH2 ACER1
Sources

GO Terms for Dermatitis, Atopic, 2

About this section

Biological processes related to Dermatitis, Atopic, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sphingolipid biosynthetic process GO:0030148 9.8 ACER1 CERS4 ELOVL1
2 keratinocyte differentiation GO:0030216 9.78 FLG ACER1
3 establishment of skin barrier GO:0061436 9.76 FLG ELOVL1
4 lipid metabolic process GO:0006629 9.71 ELOVL1 CERS4 ASAH2 ACER1
5 long-chain fatty acid biosynthetic process GO:0042759 9.67 ASAH2B ASAH2
6 ceramide biosynthetic process GO:0046513 9.63 ELOVL1 CERS4 ASAH2
7 ceramide metabolic process GO:0006672 9.61 ASAH2 ACER1
8 sphingolipid metabolic process GO:0006665 9.56 CERS4 ASAH2 ACER1
9 sphingosine biosynthetic process GO:0046512 9.43 ASAH2B ASAH2 ACER1
10 ceramide catabolic process GO:0046514 9.1 ASAH2B ASAH2 ACER1

Molecular functions related to Dermatitis, Atopic, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ceramidase activity GO:0102121 9.26 ACER1 ASAH2
2 N-acylsphingosine amidohydrolase activity GO:0017040 9.1 ASAH2B ASAH2 ACER1
Sources

Sources for Dermatitis, Atopic, 2

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....